Journal article
Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement
Abstract
INTRODUCTION: Several recent randomized trials evaluated the impact of adjuvant immune checkpoint inhibitor (ICI)-based therapy on post-surgical outcomes in renal cell carcinoma (RCC), with disparate results. The objective of this consensus statement is to provide data-driven guidance regarding the use of ICIs after complete resection of clear-cell RCC in a Canadian context.
METHODS: An expert panel of genitourinary medical oncologists, …
Authors
Lalani A-KA; Kapoor A; Basappa NS; Bhindi B; Bjarnason GA; Bosse D; Breau RH; Canil CM; Cardenas LM; Castonguay V
Journal
Canadian Urological Association Journal, Vol. 17, No. 5, pp. e154–e163
Publisher
Canadian Urological Association Journal
Publication Date
May 2023
DOI
10.5489/cuaj.8381
ISSN
1911-6470